Children’s Hospital of Philadelphia Researchers Reveal New Hope for Chemotherapy-Resistant Neuroblastoma Patients
The study identifies malignant persister cells that enable chemotherapy resistance in high-risk neuroblastoma, providing new therapeutic targets for future treatments.
Researchers at Children’s Hospital of Philadelphia used single‑nucleus RNA sequencing and whole‑genome sequencing of 20 pediatric high‑risk neuroblastoma samples to uncover malignant persister cells that evade chemotherapy by entering a dormant, non‑cycling state. This discovery identifies a new therapeutic target that could prevent relapse and improve outcomes for children with this aggressive tumor.
By revealing the cellular basis of relapse, the study opens avenues for developing drugs that specifically eradicate persister cells, potentially reducing relapse rates and improving survival in high‑risk neuroblastoma patients.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Updates in Diagnosis, Management, and Treatment of Neuroblastoma
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study